Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2020 07:00 ET | Source: Imara, Inc.

Imara to Webcast Conference Call of Second Quarter 2020 Financial Results

BOSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
July 30, 2020 07:00 ET | Source: Imara, Inc.

Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
June 29, 2020 16:01 ET | Source: Imara, Inc.

Imara Added to Membership of U.S. Small-Cap Russell 2000® Index

BOSTON, June 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
June 12, 2020 07:00 ET | Source: Imara, Inc.

Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress

Showed statistically significant increase in red blood cells containing fetal hemoglobin (F-cells) and dose-dependent increase in fetal hemoglobin percentage in high-dose group after 24 weeks of...
May 21, 2020 07:00 ET | Source: Imara, Inc.

Imara to Present Data on IMR-687 in Sickle Cell Disease at the 25th Annual European Hematology Association (EHA) Congress

BOSTON, May 21, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
May 07, 2020 07:00 ET | Source: Imara, Inc.

Imara Reports First Quarter 2020 Financial Results and Business Highlights

Strengthened Board of Directors and expanded leadership team with appointment of General Counsel Continued progress toward initiation of Phase 2b clinical trials of IMR-687 in sickle cell disease and...
May 06, 2020 07:00 ET | Source: Imara, Inc.

Imara Launches ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders

BOSTON, May 06, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
May 04, 2020 07:00 ET | Source: Imara, Inc.

Imara Announces Appointment of Stephen M. Migausky as General Counsel

BOSTON, May 04, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...